psilocin mucate

Psilocin mucate is a novel, stabilized salt form of psilocin, the active metabolite of the psychedelic prodrug psilocybin. Developed to address the instability and poor bioavailability of free psilocin, this compound is formed by combining psilocin with mucic acid. Unlike psilocybin, which requires enzymatic conversion in the body to become active, psilocin mucate dissociates rapidly in the gastrointestinal tract to release free psilocin for absorption. This results in rapid onset and highly reproducible pharmacokinetics with 100% bioavailability reported in Phase 1 studies. Notably, clinical data indicate that at therapeutic doses (e.g., 4 mg), it produces anti-anxiolytic effects without hallucinogenic side effects and demonstrates a favorable safety profile. The drug is being developed primarily for neurological disorders such as chronic cluster headache but may have broader applications due to its stable oral formulation and superior pharmacokinetic properties compared to both free psilocin and its prodrug, psilocybin[1][2][5][8][9].

Brand names

Conjugated Psilocin

Other names

psilocin mucateL-130L130L 130Conjugated Psilocin